Medical Center Zara-Med EOOD

At Medical Center Zara-Med EOOD, investigators are exploring new therapies for heart failure, hypertension and high‑risk lipid disorders, aiming to improve survival and quality of life for patients with established cardiovascular disease.

• Novel lipid‑lowering agents targeting LDL‑C and triglycerides
• Studies on heart failure with preserved and reduced ejection fraction
• Combination therapy with empagliflozin for high‑risk cardiovascular patients
• Innovative antihypertensive approaches for uncontrolled hypertension

The site conducts 20 active trials with a team of 9 investigators, contributing valuable data to European cardiovascular research networks.

Research at this facility includes advanced investigations into psoriatic arthritis, focusing on both biologic and small‑molecule treatments to achieve better joint function and reduce inflammation.

• Biologic agents such as sonelokimab evaluated for ACR50 response
• Small‑molecule inhibitor zasocitinib in patients naïve to biologic DMARDs
• Comparative studies with reference therapies like risankizumab
• Long‑term safety and tolerability monitoring

These trials support the development of targeted therapies for patients suffering from chronic joint disease in the Balkans region.

The center is actively testing innovative treatments for metabolic conditions such as type 2 diabetes, hypertriglyceridemia and severe hypercholesterolemia, with the goal of reducing cardiovascular risk and improving metabolic control.

• RNA‑based therapies like plozasiran for triglyceride reduction
• Inclisiran to achieve aggressive LDL‑C targets
• Vicadrostat combined with empagliflozin for diabetic patients with hypertension
• Long‑term safety assessments of novel metabolic agents

By enrolling patients with high cardiovascular risk, the site contributes to the evidence base for next‑generation metabolic medicines.

Investigations into chronic spontaneous urticaria aim to identify effective biologic options that can quickly relieve itching and wheals, enhancing patients’ daily functioning.

• Evaluation of anti‑IgE monoclonal antibody barzolvolimab
• Weekly urticaria activity score (UAS7) as primary efficacy endpoint
• Safety and tolerability profiling over a 12‑week period
• Assessment of quality‑of‑life improvements

The trial portfolio reflects a commitment to addressing unmet needs in dermatological care within the region.

The hospital conducts studies on major depressive disorder with prominent insomnia symptoms, testing adjunctive agents that may accelerate symptom relief and prevent relapse when combined with standard antidepressants.

• Adjunctive seltorexant added to SSRI/SNRI therapy
• Measurement of depressive symptom improvement and relapse delay
• Evaluation of sleep‑related outcomes alongside mood changes
• Monitoring of short‑ and long‑term safety in a psychiatric population

These efforts support the development of more comprehensive treatment strategies for patients struggling with mood disorders in Bulgaria.